Introduction
first suggested that neonatal hyperthyroidism might be caused by transplacental passage of longacting thyroid stimulator (L.A.T.S.) . This immunoglobulin (IgG) is found in the serum of some patients with hyperthyroidism due to Graves's disease and has with few exceptions been present in the serum of both the mother and child in cases of neonatal hyperthyroidism. Thomson and Riley (1966) , however, described a case in which L.A.T.S. was not detectable in the mother or child. Adams and Kennedy (1967) noted the existence of another immunoglobulin in the serum of patients with Graves's disease, which they termed L.A.T.S. protector (L.A.T.S.P.), since it was able to compete with L.A.T.S. for binding to human thyroid fractions in vitro but did not stimulate mouse thyroid in the in-vivo McKenzie bioassay (Adams and Kennedy, 1971) or monkey thyroid (Knight and Adams, 1973) . L.A.T.S.P. has been shown to stimulate human thyroid both in vivo (Adams et al., 1974) and in vitro (Kendall-Taylor, 1973; Shishiba et al., 1973) , and since unlike L.A.T.S. it is present in most patients with Graves's disease (Stewart et al., 1973) it has been suggested that it is likely to be a human thyroid stimulator responsible for the hyperthyroidism of Graves's disease. We report a case of neonatal hyperthyroidism in which no L.A.T.S. could be detected in the mother or infant, but in which L.A.T.S.P. was present in the mother's serum.
Patients
The mother, aged 25 years, developed hyperthyroidism due to Graves's disease at the age of 12, when her basal metabolic rate was +45%. She was treated initially with potassium perchlorate and later with carbimazole. She relapsed on several occasions when, antithyroid drugs were withdrawn and at age 20 underwent a partial thyroidectomy. Thyroid tissue showed changes compatible with hyperthyroidism, including focal lymphocytic infiltration with formation of germinal centres but no Askanazy cell change. She remained euthyroid thereafter. Her baby was born when she was 23 years of age. Eye signs of Graves's disease were present throughout, consisting of bilateral exophthalmos and left-sided lid retraction, but these did not necessitate treatment. At no time was pretibial myxoedema observed though slight splenic enlargement was noted before the thyroidectomy.
The Child was born three weeks prematurely and weighed 2,180 g. At birth she was noted to be hyperkinetic, with a tachycardia of 140/ min when resting, staring eyes, and a goitre. A thyroid function test at 3 days confirmed hyperthyroidism and she was treated with carbimazole 2-5 mg six-hourly and Lugol's iodine 1 drop eight-hourly from the tenth to 27th days with marked clinical improvement. Treatment was then withdrawn. Fourteen days later there was clinical and biochemical evidence of relapse of the hyperthyroidism and treatment was reinstituted in decreasing doses till she was 9 months of age. Withdrawal was uneventful and she subsequently thrived.
Methods
Routine thyroid function tests included measurement of the serum protein-bound iodine (P.B.I.) on an AutoAnalyzer, residual thyroid hormone binding test Amersham) , and determination of the effective thyroxine ratio (E.T.R.; Mallinkrodt).
Thyroid-stimulating hormone (T.S.H.) was measured by radioimmunoassay using the method of Hall et al. (1971) 395 0±102-8 58-0±8-5 50 mg equivalent thyroid tissue + 1-5 ml from mothert eResponse is measured by (blood radioactivity 24 hours after injection of stimulus)/ (blood radioactivity at time of injection of stimulus) x 100%. tFinal volume per mouse adjusted to 3 ml.
Discussion
The role of L.A.T.S. in the development of hyperthyroidism in Graves's disease was questioned by McKenzie (1972) and Solomon and Chopra (1972) . The relationship of L.A.T.S. to hyperthyroidism in the neonate was discussed by Maisey and Stimmler (1972) , and here the evidence for a direct effect is much stronger though some discrepancies still exist.
The evidence for Graves's disease in the mother in our case was both clinical and biochemical, the patient having been thyrotoxic and having the eye signs associated with Graves's disease. There was also strong clinical and biochemical evidence for the neonatal hyperthyroidism. The absence of circulating L.A.T.S. in the mother and baby soon after birth was surprising but the presence of L.A.T.S.P. in the mother's serum suggest that this immunoglobulin may also have a role in the pathogenesis of neonatal hyperthyroidism. Possibly also the case of neonatal hyperthyroidism reported by Thomson and Riley (1966) was due to L.A.T.S.P. The mother had the eye signs of Graves's disease and thyroglobulin antibodies were present in her serum. As in our case L.A.T.S. was not detectable in the mother or the child.
In the present case a raised serum T.S.H. level was found in the mother 14 months after partial thyroidectomy. This is a common finding after thyroidectomy but subsequent tests showed that the serum T.S.H. level had fallen to the normal range, that there was no response to T.R.H., and that routine thyroid function indices had moved to the upper end of the normal range. This trend towards recurrence of the original disorder may have been due to L.A.T.S.P.
